YDES — YD Bio Limited Stock Price, Chart & AI Report

Positive Aug 31, 2026 • 22:00 UTC GlobeNewswire Inc. • Yd Bio Limited

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio (Nasdaq: YDES), a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced H1 2026 results showing 315% revenue growth to $846.5 million and net income of $6.7 million. The profitability was primarily driven by a $9.8 million non-cash gain from warrant liability fair value changes. Excluding this adjustment, the company reported an operational net loss of $3.1 million. Revenue growth was fueled by large orders including a $327 million Fetroja order, though gross margins were pressured by lower-margin sales. The company is expanding its laboratory network, advancing exosome manufacturing, and pursuing strategic acquisitions while managing cash burn.

YDES YDESW DNA methylation cancer detection revenue growth profitability warrant liabilities molecular diagnostics

Sentiment note

The company achieved significant 315% revenue growth and transitioned to net profitability in H1 2026. However, the profitability is heavily dependent on non-cash warrant liability adjustments ($9.8M), and the underlying operational performance shows a net loss of $3.1M when adjusted. The company is expanding operations and pursuing strategic initiatives, but faces challenges including supplier concentration, cash burn ($3.3M decrease in cash), and margin pressure from large orders. The positive sentiment reflects strong top-line growth and strategic momentum, tempered by operational losses and cash runway concerns.

Positive Aug 25, 2026 • 12:00 UTC GlobeNewswire Inc. • Yd Bio Limited

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

YD Bio announced the publication of a peer-reviewed article in Nutrients journal co-authored with physicians from Taiwan's Chronic Disease Healthcare Association and Future Health Institute. The article explores how omega-3, vitamin D3, and vitamin K2 affect cardiovascular, neurological, and skeletal health. This publication expands YD Bio's physician-partnership initiative beyond product development into peer-reviewed research.

YDES YDESW peer-reviewed publication nutraceuticals physician partnership lipid-soluble nutrients heart-brain-bone axis Taiwan healthcare collaboration

Sentiment note

The company successfully published peer-reviewed research in a reputable journal, validating its scientific approach to consumer health products. This demonstrates credibility and supports the expansion of its physician-partnership model, which is a key strategic initiative. The publication adds scientific rigor to their business model and positions them favorably for future collaborations.

Positive Jul 2, 2026 • 12:00 UTC GlobeNewswire Inc. • Yd Bio Limited

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.

YDES YDESW DNA methylation cancer detection clinical laboratory CLIA certification CAP accreditation laboratory expansion

Sentiment note

The company achieved significant regulatory expansion by obtaining licenses in two highly regulated states (Rhode Island and Pennsylvania), bringing its multi-state footprint to 46 states plus D.C. and Guam. This expansion directly supports the company's early cancer detection operations and broadens patient access, representing operational progress and growth in its diagnostic platform.

Neutral Apr 30, 2026 • 22:00 UTC GlobeNewswire Inc. • Yd Bio Limited

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased operating expenses from business expansion. The company ended 2025 with $6.0 million in cash and outlined 2026 strategic priorities including FDA submissions for its Limbal Stem Cell platform and pancreatic cancer detection program, along with planned M&A activities.

YDES YDESW DNA methylation cancer detection ophthalmologic innovations pharmaceutical sales Limbal Stem Cell platform pancreatic cancer early detection FDA regulatory pathway

Sentiment note

Mixed financial performance with positive revenue growth (17% increase) and successful business combination, but offset by significant net loss expansion ($8.3M vs $1.4M), declining gross margins due to product mix shift, and substantial warrant liability charges. While management commentary shows optimistic forward guidance with multiple clinical milestones planned for 2026, the deteriorating profitability and low cash position ($6.0M) present near-term operational concerns.

Positive Dec 16, 2025 • 14:00 UTC GlobeNewswire Inc. • Dr. Ethan Shen

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited plans to establish a new U.S. operations center in California to accelerate clinical development, regulatory engagement, and commercial access for cancer diagnostics and exosome-based therapeutics.

YDES YDESW biotechnology cancer detection DNA methylation operations expansion clinical development

Sentiment note

Company is expanding operations, investing in U.S. market, recruiting talent, and strategically positioning for clinical and commercial growth